Comparator: fosaprepitant dimeglumine

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Chemotherapy-Induced Nausea and VomitingChemotherapy-Induced Nausea and Vomiting (CINV)

Phase 3

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)

CompletedNCT00337727

Merck Sharp & Dohme LLCChemotherapy-Induced Nausea and Vomiting

Start: 2007-01-01End: 2008-11-19Updated: 2017-06-02

Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)

CompletedNCT00619359

Merck Sharp & Dohme LLCChemotherapy-Induced Nausea and Vomiting (CINV)

Start: 2008-02-29End: 2009-06-30Updated: 2017-03-21

Related Papers

Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region

Current Medical Research and Opinion2014-06-0915 citations